Overview

Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Status:
Not yet recruiting

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Blinatumomab
Cyclophosphamide
Cytarabine
Dexamethasone
Inotuzumab Ozogamicin
Mercaptopurine
Methotrexate
Prednisone
Rituximab
Vincristine